Thalidomide Survivors Contribution Program

Welcome to the website for the Thalidomide Survivors Contribution Program. The purpose of this website is to provide visitors with information and updates relating to the program.


In spring 2015, a federal support package for Canadian Thalidomide Survivors was announced. The support package includes:




Ongoing Support PaymentsIf your health has gotten worse as a result of Thalidomide since the 1991 assessment or since your last TSCP assessmentIf you did not receive a payment from the Extraordinary Assistance Plan in 1991Extraordinary Medical Assistance Fund (“EMAF”)The Ongoing Support Payment for the 2018-2019 FY will be issued in April of 2018. If you wish to change how you are receiving your annual Ongoing Support Payment, please complete and submit a new Ongoing Support Payment form and check the “Change Requested” box on the first page of the form. The change will take effect starting with the next Ongoing Support Payment following approval of the form once submitted. The Ongoing Support Payment for the 2018-2019 FY will be issued in April of 2018.Reassessment may be requested once per year between April 1st of the current year and March 31st of the next year unless there is an urgent need. Urgent requests will be reviewed on a case by case basis to decide if the request will be granted. Any increase to a Survivor’s Ongoing Support Payment amount as a result of a change in disability level would take effect April 1st of the next Fiscal Year. If you wish to request reassessment, please complete and submit a Reassessment form.The deadline to submit the proof and a completed application to the Administrator has passed. No further applications are being accepted.Survivors have access to an Extraordinary Medical Assistance Fund (“EMAF”) twice per fiscal year which was created to help survivors cover costs relating to their extraordinary health support needs such as specialized surgeries and home or vehicle adaptations that are not otherwise covered by provincial/territorial healthcare plans or by other service providers. If you wish to request EMAF funding, please complete and submit an EMAF Application. There are two deadlines for the 2017-2018 FY:Deadline #1: postmarked by September 15, 2017Deadline #2: postmarked by January 15, 2018.





Crawford & Company (Canada) Inc. is funded by Health Canada to deliver the Government of Canada’s Thalidomide Survivors Contribution Program. The views expressed herein do not necessarily represent the views of Health Canada.